We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lazertinib Mesylate.
- Abstract
The article provides information on lazertinib mesylate. Lazertinib, a kinase inhibitor of epidermal growth factor receptor (EGFR), is an antinoeplastic agent. It is indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Also mentioned are its dosage and administration, common adverse effects, and drug interactions.
- Subjects
THERAPEUTIC use of antineoplastic agents; THERAPEUTIC use of monoclonal antibodies; COMBINATION drug therapy; PULMONARY embolism; PATIENT education; PROTEIN-tyrosine kinase inhibitors; VEINS; VENOUS thrombosis; EXANTHEMA; ORAL drug administration; INTERSTITIAL lung diseases; PHARMACY information services; DRUG approval; THROMBOEMBOLISM; DRUG interactions; LUNG cancer; GENETIC mutation; EPIDERMAL growth factor receptors; PHARMACODYNAMICS
- Publication
American Journal of Health-System Pharmacy, 2025, Vol 82, Issue 2, p3
- ISSN
1079-2082
- Publication type
Academic Journal
- DOI
10.1093/ajhp/zxae282